Efficacy of Nab-PHP Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nab paclitaxel, Docetaxel and Carboplatin, Trastuzumab + Pertuzumab.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Comparing the Efficacy of Nab-PHP and TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer, A Multicenter, Randomized, Phase III Clinical Trial
Overview
The aim of this study is to evaluate the efficacy of nab-paclitaxel (on days 1 and 8 of a 21-day cycle) compared to the standard regimen of docetaxel plus carboplatin, both combined with trastuzumab and pertuzumab, as neoadjuvant therapies for HER2-positive breast cancer.
Interventions
- Drug Nab paclitaxel
Nab-paclitaxel (on days 1 and 8 of a 21-day cycle) - Drug Docetaxel and Carboplatin
Docetaxel 75 mg/m2(day 1) + Carboplatin (AUC=6) (day 1) - Drug Trastuzumab + Pertuzumab
Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and pertuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Primary outcome measures
- Pathological Complete Response (pCR) [Time frame: through study completion, up to 6 months]
Secondary outcome measures (7)
- Event-Free Survival (EFS) [Time frame: 5 years after surgery]
- Invasive Disease-Free Survival (iDFS) [Time frame: 5 years after surgery]
- Safety-Number of adverse events and serious adverse events. [Time frame: up to 1 year]
- Tolerability-Dose adjustment rate and withdrawal rate of chemotherapy drugs [Time frame: up to 1 year]
- Residual Cancer Burden (RCB) [Time frame: up to 6 months]
- EORTC QLQ-C30 score [Time frame: up to 1 year]
- EORTC QLQ-BR23 score [Time frame: up to 1 year]
Eligibility criteria
Inclusion criteria
Age: 18-70 years old.
Clinical Tumor Stage: T2-T4d, or T1c with axillary lymph node positivity.
Histologically confirmed HER2-positive invasive breast cancer:
Note: HER2 positivity is defined as at least one assessment (either initial testing or central review) by the participating center's pathology department demonstrating tumor cells with immunohistochemistry (IHC) staining intensity of 3+ or confirmation by fluorescence in situ hybridization (FISH).
Clinically measurable disease: Lesion measurable by ultrasound or MRI (optional) within 1 month prior to randomization.
Adequate organ and bone marrow function within 1 month prior to chemotherapy initiation (no contraindications to chemotherapy):
- Absolute neutrophil count (ANC) ≥ 2.0 × 10⁹/L
- Hemoglobin ≥ 100 g/L
- Platelet count ≥ 100 × 10⁹/L
- Total bilirubin < 1.5 × upper limit of normal (ULN)
- Serum creatinine < 1.5 × ULN
- Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < 1.5 × ULN
Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 55% assessed by echocardiography.
Women of childbearing potential: Negative serum pregnancy test within 14 days prior to randomization.
Performance status: Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Informed consent: Provision of signed written informed consent.
Exclusion criteria
Stage IV (metastatic) breast cancer.
Bilateral breast cancer.
Prior systemic therapy or radiotherapy for the current breast cancer diagnosis, including chemotherapy, endocrine therapy, or targeted therapy.
History of a second primary malignancy, except for adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix.
Major surgery unrelated to breast cancer within 4 weeks prior to enrollment, or incomplete recovery from prior major surgery.
Significant cardiac disease or dysfunction, including but not limited to:
- History of congestive heart failure or systolic dysfunction (LVEF < 50%)
- High-risk uncontrolled arrhythmias (e.g., atrial tachycardia, resting heart rate > 100 bpm, clinically significant ventricular arrhythmia \[e.g., ventricular tachycardia\], or higher-grade atrioventricular block \[i.e., Mobitz II second-degree or third-degree heart block\])
- Angina pectoris requiring anti-anginal medication
- Clinically significant valvular heart disease
- Electrocardiogram (ECG) evidence of transmural myocardial infarction
- Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg)
Presence of any other severe, uncontrolled medical condition that, in the investigator's judgment, constitutes a contraindication to chemotherapy.
Known history of allergy to any component of the study drugs; patients with a history of immune deficiency diseases, including HIV positivity, or patients with other acquired or congenital immune deficiency diseases, or a history of organ transplantation.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- Henan cancer hospital — Zhengzhou
Identifiers
NCT: NCT07057427 · HELEN-006Lite